Taflopress Rompharm 0.015 mg/ml eye drops, solution

Therapeutic indications

Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.

As monotherapy in patients:

- who would benefit from preservative free eye drops;

- insufficiently responsive to first line therapy;

- intolerant or contra-indicated to first line therapy.

As adjunctive therapy to beta-blockers.

Tafluprost is indicated in adults ≥ 18 years.

Tafluprost is a fuorinated analogue of prostaglandin F2α. Tafluprost acid, the biologically active metabolite of tafluprost, is a highly potent and selective agonist of the human prostanoid FP receptor. Tafluprost acid has a 12-fold higher affinity for the FP receptor than latanoprost. Pharmacodynamic studies in monkeys indicate that tafluprost reduces intraocular pressure by increasing the uveoscleral outflow of aqueous humour.